Chen Yuan1, Lindsay Renfro2, Pratibha B Ambadwar2, Fang-Shu Ou3, Howard L McLeod4, Federico Innocenti5, Jeffrey A Meyerhardt6, Brian M Wolpin6, Richard M Goldberg7, Axel Grothey8, Charles S Fuchs9, Kimmie Ng6. 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. chen_yuan@dfci.harvard.edu. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 3. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA. 4. DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL, USA. 5. Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 6. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. 7. West Virginia University Cancer Institute, Morgantown, WV, USA. 8. Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. 9. Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA.
Abstract
PURPOSE: The relationships of genetic variation in the vitamin D pathway with circulating 25-hydroxyvitamin D3 [25(OH)D] levels and survival remain largely unknown for patients with metastatic colorectal cancer (mCRC). METHODS: Among 535 patients participating in a randomized trial ofchemotherapy for mCRC, we prospectively measured baseline plasma 25(OH)D and examined 124 tagging single-nucleotide polymorphisms (SNPs) within seven genes in the vitamin D pathway, including five SNPs associated with circulating 25(OH)D levels in previous genome-wide association studies (GWAS). We evaluated whether these SNPs were associated with plasma 25(OH)D levels and patient outcome (overall survival, time to progression, and tumor response), using linear, logistic, and Cox proportional hazards regression. RESULTS: We observed a significant association between 25(OH)D levels and an additive genetic risk score determined by the five GWAS-identified SNPs (p = 0.0009). We did not observe any direct association between 25(OH)D-associated SNPs, individually or as a genetic risk score, and patient outcome. However, we found a significant interaction between 25(OH)D levels and rs12785878 genotype in DHCR7 on overall survival (pinteraction = 0.02). CONCLUSION: Germline genetic variation in the vitamin D pathway informs baseline 25(OH)D levels among patients with mCRC. The association between 25(OH)D levels and overall survival may vary by DHCR7 genotype. ClinicalTrials.gov Identifier: NCT00003594 ( https://clinicaltrials.gov/ct2/show/NCT00003594 ).
RCT Entities:
PURPOSE: The relationships of genetic variation in the vitamin D pathway with circulating 25-hydroxyvitamin D3 [25(OH)D] levels and survival remain largely unknown for patients with metastatic colorectal cancer (mCRC). METHODS: Among 535 patients participating in a randomized trial of chemotherapy for mCRC, we prospectively measured baseline plasma 25(OH)D and examined 124 tagging single-nucleotide polymorphisms (SNPs) within seven genes in the vitamin D pathway, including five SNPs associated with circulating 25(OH)D levels in previous genome-wide association studies (GWAS). We evaluated whether these SNPs were associated with plasma 25(OH)D levels and patient outcome (overall survival, time to progression, and tumor response), using linear, logistic, and Cox proportional hazards regression. RESULTS: We observed a significant association between 25(OH)D levels and an additive genetic risk score determined by the five GWAS-identified SNPs (p = 0.0009). We did not observe any direct association between 25(OH)D-associated SNPs, individually or as a genetic risk score, and patient outcome. However, we found a significant interaction between 25(OH)D levels and rs12785878 genotype in DHCR7 on overall survival (pinteraction = 0.02). CONCLUSION: Germline genetic variation in the vitamin D pathway informs baseline 25(OH)D levels among patients with mCRC. The association between 25(OH)D levels and overall survival may vary by DHCR7 genotype. ClinicalTrials.gov Identifier: NCT00003594 ( https://clinicaltrials.gov/ct2/show/NCT00003594 ).
Authors: D Zehnder; R Bland; M C Williams; R W McNinch; A J Howie; P M Stewart; M Hewison Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: D Hunter; M De Lange; H Snieder; A J MacGregor; R Swaminathan; R V Thakker; T D Spector Journal: J Bone Miner Res Date: 2001-02 Impact factor: 6.741
Authors: Jeffrey A Meyerhardt; Jeffrey A Sloan; Daniel J Sargent; Richard M Goldberg; Michael Pollak; Roscoe F Morton; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts Journal: J Clin Oncol Date: 2003-12-09 Impact factor: 44.544
Authors: Jeffrey B Cheng; Michael A Levine; Norman H Bell; David J Mangelsdorf; David W Russell Journal: Proc Natl Acad Sci U S A Date: 2004-05-05 Impact factor: 11.205
Authors: H G Pálmer; J M González-Sancho; J Espada; M T Berciano; I Puig; J Baulida; M Quintanilla; A Cano; A G de Herreros; M Lafarga; A Muñoz Journal: J Cell Biol Date: 2001-07-23 Impact factor: 10.539